Lingying Wu
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Emerging Leaders
not ranked
Current Leaders
#2154 pts
All-Time Leaders
#1,66117 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2017. 9 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
Phase 2RecruitingHansoh BioMedical R&D Company
5
impact
Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial
Phase 2UnknownChinese Academy of Medical SciencesStudy Chair
3
impact
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
3
impact
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
Phase 2RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
A Single-Arm, Open-Label, Multicentre, Phase II Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
Phase 2UnknownShanghai Henlius Biotech
2
impact
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With Fluzoparib Capsules Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.
2
impact
A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 3RecruitingHansoh BioMedical R&D Company
1
impact
An Open, Multi-dose, Dose Escalation and Cohort Expansion, Phase Ⅰ Study of the Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours.
Phase 1UnknownCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
0
impact
An Open-label, Multicenter Phase Ib/Ⅱ Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Paclitaxel Injection in Patients With Platinum-resistant Ovarian Cancer
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd
0
impact
Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
N/ACompletedAstraZeneca
0
impact
Induced and Concurrent Serplulimab Plus Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for Stage III-IVA Cervical Cancer: a Prospective, Multicenter, Randomized, Open Controlled Clinical Trial
Phase 2ActiveCancer Institute and Hospital, Chinese Academy of Medical Sciences
0
impact
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase Ш Clinical Study to Evaluate the Efficacy and Safety of First-line Treatment With SG001 Plus Chemotherapy±Bevacizumab Versus Placebo Plus Chemotherapy±Bevacizumab for PD-L1 Positive (CPS≥1) Women With Recurrent, or Metastatic Cervical Cancer
Phase 3Not Yet RecruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
0
impact
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of WJB001 Capsules in Dose Escalation, Dose Expansion, and Efficacy Expansion in Patients With Advanced Solid Tumors
Phase 2RecruitingWigen Biomedicine Technology (Shanghai) Co., Ltd.
0
impact
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin/Cisplatin and Paclitaxel) vs Chemotherapy (Carboplatin/Cisplatin and Paclitaxel)in Patients With Advanced Cervical Cancer
Phase 3WithdrawnShanghai Henlius Biotech
0
impact
A Phase Ib/II, Open-label, Multicenter Clinical Study to Evaluate the Antitumor Activities, Safety, and Tolerability of IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Phase 2CompletedInxMed (Shanghai) Co., Ltd.
0
impact
A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors
Phase 2RecruitingAdvenchen Laboratories, LLC
0
impact
An Observational, Non-interventional Study of Niraparib Maintenance Treatment in Patients With Ovarian Cancer After Frontline Platinum-based Chemotherapy
N/AUnknownLing-Ying Wu
0
impact
An Open, Multi-cohort, Multi-center Phase II Basket Clinical Study of RC48-ADC Monotherapy in the Treatment of HER2-expressing (HER2-positive and HER2 Low Expression) Gynecological Malignancies
Phase 2UnknownRemeGen Co., Ltd.
0
impact
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies
Phase 2CompletedZai Lab (Shanghai) Co., Ltd.
0
impact
Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer: a Multicenter, Open, Phase 2 Clinical Study
Phase 2UnknownChinese Academy of Medical SciencesStudy Chair
0
impact
An Multicenter, Randomized，Double-blind, Controlled Clinical Study of Nimotuzumab in Combined With First-line Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Squamous Cell Carcinoma
Phase 3CompletedBiotech Pharmaceutical Co., Ltd.Study Chair
0
impact